Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

European Commission Grants "2+1 Immunization Schedule" for Hexyon® 6-in-1 Paediatric Vaccine


News provided by

Sanofi Pasteur MSD

05 Mar, 2015, 08:00 GMT

Share this article

Share toX

Share this article

Share toX

- This release is not for French press

LYON, France, March 5, 2015 /PRNewswire/ --

 

This decision opens the way to making Hexyon® available to more infants in European countries  

Sanofi Pasteur MSD announced today that the European Commission has granted a new vaccination schedule of the 6-in-1 paediatric vaccine Hexyon® (DTaP-IPV-HB-Hib vaccine) for a "2+1" schedule of administration, in addition to other possible schedules already approved for this vaccine.

This additional "2+1" schedule is based on a primary immunization with 2 doses followed by 1 booster vaccination around one year of age. This new schedule for Hexyon® comprises a total of 3 doses* and it is simplified compared to the already approved schedules which comprise 4 doses in total (3 doses in primary vaccination and 1 booster dose).

European countries recommending a "2+1" schedule for infant vaccination include France, Italy, Austria, Denmark, Norway and Sweden.

"This approval from the European Commission is another demonstration of Hexyon's good immunogenicity and safety profile", said Dr. Stephen Lockhart, Vice-President Development of Sanofi Pasteur MSD. "We are delighted to be able to offer Hexyon ® with this new schedule, which means that  Hexyon® can be made available to more infants in the European Union", concluded Dr Lockhart.  

The approval of this new schedule for Hexyon® follows the positive opinion from the European Medicines Agency (EMA) granted in February, based on results from a multi-center Phase III clinical trial involving 546 infants, which compared Hexyon® to one licensed hexavalent combination vaccine and that demonstrated that Hexyon® given in a 2+1 immunization schedule is safe and elicits protective immune responses against the 6 targeted diseases.

About Hexyon® 

Hexyon® is a fully liquid, ready-to-use, paediatric hexavalent vaccine.

Hexyon® was granted marketing authorisation from the European Commission in April 2013. It was developed by Sanofi Pasteur® and it is now registered in more than 70 countries worldwide.

Hexyon® is commercialised under three brands names: Hexyon® by Sanofi Pasteur MSD® in Western Europe, Hexacima® by Sanofi Pasteur® in Eastern Europe and Hexaxim® by Sanofi Pasteur® in the rest of the world.

Hexyon® combines protection against six of these major infectious diseases, which are included in the national immunisation calendars of most countries in Europe:

    1. Haemophilius influenza  type b (Hib) disease 

       Hib is a bacterium that can cause severe invasive diseases in infants, such as meningitis[1],[2]

    2. Diphtheria 

       Diphtheria is a highly contagious disease caused by the bacterium Corynebacterium diphtheriae. This germ produces a toxin that can affect the throat and skin, and can cause damage to the heart and other organs[1],[3]

    3. Pertussis (whooping cough) 

       Pertussis is a highly contagious bacterial infection of the upper respiratory tract which can cause serious illness in infants, children and adults[4]

    4. Tetanus 

       Tetanus is a serious disease caused by the bacterium Clostridium tetani, which produces a toxin that causes lockjaw and affects the body's muscles and nerves[5]. Usually the bacterium infects the body through a wound[1],[5]

    5. Poliomyelitis (Polio) 

       Polio is a highly infectious disease caused by the poliovirus, which affects the nerves and can lead to muscle weakness or paralysis[1],[6]

    6. Hepatitis B (Hep B) 

       Hep B is a viral infection that attacks the liver and can cause both acute and chronic disease[7]

Hexyon® provides new levels of efficiency** in the prevention of these six major infectious diseases 

The fully liquid, ready-to-use technology of Hexyon® eliminates the need for reconstitution[8]. By offering high immunogenicity with a good safety profile, while simplifying the vaccination process and reducing the risk of errors or injuries, Hexyon® provides new levels of efficiency for the protection of infants and toddlers against severe diseases.

Hexyon® was approved by the European Commission in April 2013. National recommendations and funding are being progressed in each country.

**New levels of efficiency refers to high immunogenicity, a favourable safety profile, and ready-to-use technology that eliminates the need for reconstitution and reduces preparation time, resulting in fewer handling errors and a lower patient risk.

About Sanofi Pasteur MSD  http://www.spmsd.com

Sanofi Pasteur MSD is a European joint venture formed between Sanofi Pasteur (the vaccine division of Sanofi) and Merck (known as MSD outside the United States and Canada). Combining innovation and expertise, Sanofi Pasteur MSD is the only European pharmaceutical company dedicated exclusively to the development of vaccines. Sanofi Pasteur MSD makes use of the combined expertise resulting from Sanofi Pasteur and Merck's research to focus on the development of new vaccines in Europe in order to produce the most effective, most acceptable and better tolerated vaccines.

References 

  1. EMA, EPAR summary for the public, EMA/137344/2013, sourced at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002796/WC500145761.pdf , accessed November 2014
  2. NHS. Haemophilus influenzae type b (Hib), sourced at: http://www.nhs.uk/conditions/hib/pages/introduction.aspx , accessed November 2014
  3. WHO. Immunization, Vaccines and Biologicals, sourced at: http://www.who.int/immunization/topics/diphtheria/en/index.html , accessed November 2014
  4. CDC. Whooping Cough (Pertussis) - Fact Sheet for Parents, sourced at: http://www.cdc.gov/vaccines/vpd-vac/pertussis/fs-parents.html , accessed November 2014
  5. WHO, Tetanus, sourced at: http://www.who.int/topics/tetanus/en/ , accessed November 2014
  6. WHO. Poliomyelitis factsheet n°114, sourced at: http://www.who.int/mediacentre/factsheets/fs114/en/ , accessed November 2014
  7. WHO. Hepatitis B, factsheet, sourced at: http://www.who.int/mediacentre/factsheets/fs204/en/index.html , accessed November 2014
  8. Summary of Product Characteristics of Hexyon®, sourced at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002796/human_med_001641.jsp&mid=WC0b01ac058001d124, accessed November 2014

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.